TruScreen Investor Presentation March 2025

1
TruScreen
Investor Presentation
March 2025

2
⚫Who is TruScreen
⚫The TruScreen Technology
⚫TruScreen Sales Strategy
⚫TruScreen Key Financials
⚫TruScreen - Our Journey and Growth Strategy
⚫TruScreen Key Markets
TruScreen

Who is TruScreen
3

4
Who is TruScreen
TruScreen Group Ltd is listed
on both the Australian (ASX)
and New Zealand (NZX) stock
exchanges, with a common
ticker code of TRU.
Shares on Issue:
552,591,116
Market Capitalisation at
27 February 2025:
NZD $19.34m
TruScreen Group Ltd is a
revenue generating Life
Science company with FY24
annual sales exceeding
NZD $2m.
TruScreen Group Ltd owns
TruScreen Pty Ltd, the
Australian operating company
that manufactures and
markets the TruScreen cervical
cancer screening system

5
Corporate Snapshot
Shares on issue552 million
Options13 million
Share priceNZ$0.035
Market capitalisationNZ$19.34 million
52 week high3.7 cents
52 week low1.5 cents
Major ShareholdersShares%
New Zealand Depository Nominee64,098,83311.6
Consolidated Nominees39,602,4007.17
Masfen Securities Limited29,050,3695.26
Bhagwanji Bhula Rama27,791,6665,03
New Zealand Central Securities27,539,5664.98
Ryan Peter Parkin20,020,0003.62
David and Adrienne Stewart12,630,0002.29
TruScreen Price History (NZX)

6
An Experienced Leadership Team
TruScreen
Group Ltd
Mr. Anthony Ho
B. Com (UNSW), CA, FAICD,
FCIS, FGIA
Non-executive Chairman
•Tony is an experienced company
director and is currently a director
and chairman of a number of listed
ASX companies.
•Tony was executive director of sales
and distribution company Arthur
Yates & Co Limited, as well as
Finance Director/CFO of listed
retailers on the ASX – M. S. McLeod
Holdings Limited (Downtown Duty
Free), Galore Group Limited
(Barbeques Galore) and Brazin
Limited (Bras N Things, Sanity
Music).
•Prior to joining commerce, Tony was
a partner of Cox Johnston & Co,
Chartered Accountants which has
since merged with Ernst & Young.
Ms. Juliet Hull
B.Nurse ATI, MBA MGSM
Non-executive Director
•Juliet Hull has an MBA from the
Macquarie Graduate School of
Management, Sydney Australia, and
a Bachelor of Nursing from the
Auckland Technical Institute.
•Juliet has more than twenty years’
experience working in Asia and
Pacific markets in Healthcare, in
sales, Marketing and leadership.
Juliet was the General
Manager/Country Director for
Johnson & Johnson Medical in New
Zealand and has held various roles
in Johnson & Johnson in Australia
and New Zealand since 2012.
Mr. Christopher Horn
B. Com (UNSW), FCA
Non-executive Independent
Director
•Chris Horn has been involved with
TruScreen for a number of years. He
is an experienced business
executive and has acted in a
number of management roles
including 20 years as a senior
partner of KPMG and its predecessor
firms.
•He is a director of a number of
private companies across a broad
range of business activities including
corporate advisory, financial
services, and funds management.
• Chris is a Commerce graduate from
the University of New South Wales,
Sydney, Australia and a Fellow of
the Institute of Chartered
Accountants in Australia and New
Zealand. Chris is also the Chair of
TruScreen’s Audit, Finance and Risk
Committee.
Dr. Dexter Cheung
B. Tech (Hons), M.Eng, PHD
Non-executive Director
•Dr. Dexter Cheung is an experienced
medical device engineer and
specialist in product research and
development. He is the Research
and Development Manager of the
respiratory humidification division of
Fisher & Paykel Healthcare, an
ASX/NZX listed healthcare company.
•With over 20 Years of experience,
Dr. Cheung brings a strong
understanding of manufacturing
processes and has worked with
suppliers and manufacturers across
the glove. Dr. Cheung’s technical
background is in opto-electronics
and expertise in medical device
engineering is highly relevant to
TruScreen, who’s cervical cancer
screening device harnesses opto-
electronic signatures for screening
results.

7
An Experienced Leadership Team
TruScreen
Group Ltd
Mr. Guy Robertson
B. Com (Hons.) CA
CFO & Company Secretary
•Guy is an experienced finance executive,
having held the positions of Director,
Company Secretary and Chief Financial
Officer of both private and ASX-listed
companies in Australia and Hong Kong.
•Guy held senior roles in the Jardine
Matheson Group of Companies, including
General Manager Finance of Franklins
Limited, Chief Operating Officer of Colliers
International Asia Pacific and Managing
Director (NSW) Jardine Lloyd Thompson.
Mr Marty Dillon
CEO
•Martin Dillon, the CEO of TruScreen Group
Ltd, skilfully managed the company’s
listing on the NZX and oversees its
strategic vision. With over 30 years of
commercial experience, he has engaged
with health and regulatory authorities
worldwide.
•Martin has held senior executive roles
including at CEO and Managing Director
level in private and public companies in
healthcare, advertising and marketing.
Professor Michael Campion
Medical Advisory Committee Chair
•Professor Michael Campion graduated from the
University of New South Wales, Australia in
1977.. He was the Scientific Program Director of
the British Society for Colposcopy and Cervical
Pathology from 1985 till 1987.
•In 1986, he received the Victor Bonney Award
from the London Obstetrics and Gynaecology
Society for his pivotal research into the role of
human papillomaviruses in the causation of
cervical cancer.
•He is the Director of the Preinvasive Unit,
Gynaecological Cancer Centre, Royal Hospital
for Women, Randwick
•He has published over sixty academic papers,
articles, book and book chapters and presented
at numerous scientific congresses.

8
About
TruScreen
Technology
Enable by AI, TruScreen provides an
accurate, real time cervical cancer
screening solution

9
TruScreen
Real-time, AI-enabled, primary cervical cancer
screening device for detection of pre-cancerous and
cancerous cervical tissue
Handheld device
What is the TRU System and how does it work? The TRU system consists of a
handheld device (HHD), intelligent cradle and a single-use-sensor (SUS).
The TruScreen device uses low level electrical and optical signals to detect cancerous
and pre-cancerous tissues. The HHD collects and analyses the data and provides
instant results, enabling clinicians/physicians to immediately plan appropriate patient
care. The device has an expected life of 5–7 years, while the disposable SUS is used
once per test per patient.
Having the SUS as a single-use item ensures there is no chance of cross-infection
between patients. The entire patient data collection and analysis is self-checked and
controlled. No tissue sample is needed to be taken. These measures ensure that
the results are reliable and consistent, and that the examination is painless and safe.
TruScreen has been used on over 1 million women and there has never
been a single adverse event reported.
Intelligent Cradle
Single Use
Sensor (SUS)

10
Optical and Electrical Tissue Differentiation
Optical Tissue Differentiation
TruScreen measures the
scattering and diffuse reflection
of Distant Red, Red, Infrared and Green light.
TruScreen detects changes in sub-surface
tissue that are not visible in visual inspection
or collected in a Pap Smear sample.
Electrical Tissue Differentiation
Squamous tissue acts as a battery and stores,
for a brief period, electrical charge.
TruScreen stimulates the cervix with low
voltage multi pulse stimulation (0.78 V) and
then measures the voltage decay of the tissue.
Powered by an AI enabled Algorithm

11
Trusted Clinical Performance
High sensitivity in
detecting CIN2+*
High specificity in
detecting CIN2+*
Extensive body of
clinical evidence
See Appendix for a full list of clinical
trials
TruScreen
®
has been
found to be as sensitive
in detecting CIN2+ as
cytology**
4
TruScreen
®
has been
found to be more
specific in detecting
CIN2+ as cytology**
4
Over 40,000
women in clinical
trials to date***
* CIN2: A cervical biopsy finding that means moderately abnormal cells were found on the surface of the cervix.
CIN2 is usually caused by infection with certain types of human papillomavirus (HPV). Source: NIH, www.cancer.gov
** Data from large observational study, Cytology used was ThinPrep
*** Total number of subjects across published and unpublished clinical studies in English, data from TruScreen device generation I and II

12
Why Choose TruScreen
TruScreen

13
TruScreen Sales
Strategy

14
Recurring Revenue Model
TruScreen manufactures two devices - one made in China for use in China, where locally manufactured products have preferential market
access, and one made in Australia for other markets
For each patient screened with the TruScreen device a new disposable Single Use Sensor (SUS) must be used. This creates a recurring
revenue model with a consumable sale for each patient screened with TruScreen.
TruScreen Sales Strategy
Focus on LMIC’s
Whilst many other medical technology companies seek to commercialize their devices in developed countries TruScreen focuses on
Low and Middle Income Countries (LMICs) such as China, Mexico, Vietnam and Zimbabwe.
Unlike the developed western markets, these countries and other LMICs have no or minimal large-scale cervical cancer screening
programs and infrastructure. This creates a gap in the market for TruScreen that is not available in the developed markets and allows
quicker market access from a relative lack of existing competition.
Unlike competing products such as cytology and HPV DNA screening TruScreen is ‘capital light’, not requiring lab infrastructure to be
established prior to commencing screening.

15
TruScreen Financials
KEY FINANCIALS
NZD (m)
FY 22
Actual
FY 23
Actual
FY 24
Actual
Sales1.71.662.1
Total Revenue2.72.22.6
COGS1.31.31.4
R&D1.50.90.9
EBITDA-2.7-2.4-2.0
Write off of Non-Current
Assets
-4.6-0.05-
Amortisation &
Depreciation
-0.6--
LOSS FOR YEAR-7.9-2.4-2.0
Net Assets3.42.53.2
Cash2.82.22.7
⚫Sales increased 27% YOY
⚫SUS Sales increased 25% YOY
⚫Revenue increased 18% YOY
⚫EBITDA improved 15% YOY
⚫Net Assets increased 28% YOY
⚫Cash increased 23% YOY
⚫China SUS/Device Pull Through increased 40% YOY
FY 24 v FY 23

16
TruScreen Financials
1
st
Half FY241
st
Half FY25% Change
Sales$0.98$1.035%
EBITDA-$1.35-$1.1316%
Operating Cash Outflow-$1.4- $0.936%
SUS Units91,620 96,480 5%
Devices429-79%
China SUS pull though
per month per device9713741%

TruScreen Journey
Building the Fundamentals 2014 -2020
Building for the Future 2020-2024
2025& Beyond
China Growth continues
Distribution of Dalton Bio IVD HPV
DNA products
Vietnam HPHA program targets
260,000 women, Uzbekistan and
Zimbabwe screening programs to
commence.
Indonesia and ASEAN commence
commercial use
Global focus on AI boosts
recognition of TruScreen
CFDA (NMPA)
approvalfor
secondgeneration
device
2017 Dec
2018 Oct
523% sales
growth in
H1
2019 May
Recognition by
World Health
I Organization
2020 Jan
ASX Listing
••••••
2014 Nov
Listing on NZAX
•••••
2020 Sep
China COGA study
2
nd
province
screening
results exceed
expectations
••
•
2023-24
COGA Blue Book and CSCCP Guidelines
include TruScreen
UNITAID recognises TruScreen’s value for
Cervical Cancer screening
WHO invited TruScreen to participate in
Key AI meeting for cervical cancer
screening
Vietnam – HPHA large scale screening
MOU signed
Commence large
scalepilotprograms
inChinawithCDC
andCOGA
2018 Jul
Migration to NZX
2018 Dec
2022
Managing COVID-19 challenges
Cost reduction
Manufacturing and business
development in China
Completion of major COGA study
Strengthen distributor
arrangement
in Vietnam

18
Market Expansion
FY 24 TruScreen sales grow 27% YOY, exceeding China and APAC CAGR forecasts for HPV screening
(10%).
Business Market Insights
June 2023:
The Asia Pacific CIN & HR-HPV
treatment market is expected to
grow from US$ 2,738.94 million
in 2023 to US$ 3,949.99 million
by 2028.
It is estimated to grow at a CAGR
of 7.6% from 2023 to 2028.
1
2
HPV Test Market Revenue (Million USD) and Growth Rate (2018-2028)

19
Device installations and SUS Sales
This is not a forecast of performance or expected results
Where we are
0
50
100
150
200
250
300
350
0
50
100
150
200
250
300
FY19FY20FY21FY22FY23FY24FY25FY26
Installed Devices
SUS Usage
Thousands
Field1
'SUS Usage', 'Installed Devices' by 'Field1'
Installed DevicesSUS Sales

Growth Strategies
Strengthen China
Distribution Capability via
Strategic Partnership with
DaltonBio
Focus on key growth
provinces
Shandong, Jiangsu,
Guangdong, Hunan,
Zhejiang, Guangxi
(Total popn 496m)
Strengthen vertical Asian
market from Indonesia
through China
Target Govt and NGO
funded programs in
Zimbabwe, Vietnam, Mexico
and Uzbekistan
Market expansion to
continue with China the
key focus
20
Build on International
NGO Recognition (WHO,
UNITAID, CHIA, COGA ,
CSCCP) to build
acceptance and remove
barriers to sale

Growth Strategies
Focus on countries with
limited or nil cervical
screening capability
Developing strategic
partnerships for
complementary woman’s
health services
Expand product portfolio
to include Dalton Bio HPV
related IVD products DNA
tests, including HPV DNA
tests and self sampling
Reduce SUS and Device
COGS and increase
margins
Capitalise on global focus
on AI enabled cervical
cancer technologies – e.g
WHO
21

22
TruScreen & Dalton Bioscience
• MOU signed February 2025 between TruScreen Group Ltd and Hangzhou Dalton Bioscience
•Collaborate for expansion:
1.TruScreen to distribute globally (excluding USA and Canada) via selected distributors
DaltonBio HPV related IVD products including DNA tests and Self Sampling.
2.DaltonBio to explore opportunities to assist TruScreen’s AI enabled real time cervical
screening device within its distribution network, notably its distributors in China and
South America

TruScreen’s presence and global markets*
China
477M
RUSSIA
48M
&
CENTRAL
ASIA
13M
ASEAN &
INDONESIA
142M
MEXICO
46M
VIETNAM
36M
SAUDI
11M
SOUTHERN
& CENTRAL
AFRICA
134M
INDIA
468M
UZBEKISTAN
12M
Current Markets
Targeting commercial rollout
Markets under review
* Number of eligible women to of screening age: CIA World Fact Book Women 15-64,
23

24
China
TruScreen’s largest market
and No 1 Focus for Sales
Over 477 million women of screening
age, with 158 million women needing
to be screened each year*
High government support for
cervical cancer screening
Made in China
status from 2021 – preferred market
access in China – NMPA approval
* CIA World Fact Book May 2024 Women aged 15-64 yrs

25
China
China Sales represented 78% of FY2024 Global Sales.
This is a result of a continued focus by TruScreen as our key target market and years of pushing to have TruScreen recognized by key
institutions as a recommended method for the primary screening for cervical cancer.
Inclusion in Official Screening Guidelines
1. TruScreen listed in COGA (Chinese Obstetricians and Gynaecologists Association) Blue Book
2. TruScreen Listed in CSCCP (Chinese Society for Colposcopy and Cervical Pathology) Guideline
Growing installation base and increasing consumable use
101 hospitals which are active users of TruScreen for cervical cancer screening using an average of 134 consumable
Single Use Sensors per device per month (UP 50% ON THE PREVIOUS YEAR).
Total Consumable (Single Use Sensor) sales for FY2024 were a 24% increase on FY2023

26
Provincial Pricing Approvals from 11
Provincial Pricing Approvals submitted: 10
Focus on Key Expansion Provinces
Shandong, Jiangsu, Guangdong, Hunan, Zhejiang, Guangxi
Accelerate Adoption in National Health Check program
(Guangdong) and Private Users (Jiangsu)
China
TruScreen installed in Affiliated
Hospital of Nantong University
the leading hospital in Jiangsu
province
Top 6 Hospitals use over 500
SUS per month per device
25 Hospitals currently in tender
process to procure TruScreen
Beijing has approved TruScreen
for a Public Health Scheme
Rebate
Provincial price increases
approved

27
Vietnam
36 million women of
screening age*
No centralised
screening programs
Booming economy
and middle class
April 12, 2025: Launch of Ho Chi Minh City Public Health Association (HPHA)
screening program.
The HPHA will conduct of a 5-year program screening at least 260,000 women in Ho Chi
Minh City. The project, titled ‘Community Based Proactive Cervical Cancer Screening
Program’ will be activated through existing District Health and Community Clinics, including
mobile screening.
Inclusion in Ministry of Health Technical List
In 2024 the Vietnam Ministry Of Health (MOH) listed TruScreen on the National Technical
List of approved technologies for cervical cancer screening, reduces the hospital purchasing
approval time from 18 months to 2 – 4 weeks.
Roll out to Target Hospitals
TruScreen’s distributor GHS is targeting 64 hospitals over FY2025 and FY2026.

28
South East Asia
Uzbekistan
ASEAN and Indonesia Distribution
TruScreen has distribution for Thailand, Singapore and Malaysia.
This will give TruScreen a continuous geographic East Asian market from Indonesia (where
product registration has recently been approved), through the ASEAN region, Indo- China and
north through China.
TruScreen has appointed PT Mawar Mitra Medika for distribution in Indonesia, the world’s
largest Islamic nation, where TruScreen was recently invited to present to MoH officials on the
use of AI for Cervical Cancer Screening. Product registration is completed and commercial
sales due to commence in April 2025.
Public Screening Program
TruScreen is in discussion with the Uzbekistan Ministry of Health and representatives
from the office of the President for use as a screening solution in regional centres and
remote communities.
Product registration is expected to be completed in early March 2025, which will be
followed by a validation program in Tashkent and a planned installation into all 14
women’s clinics in Tashkent, and then a roll out into other cities and provinces.
12 million women
of screening age
142 million women of
screening age

29
Zimbabwe
Use in Public Screening Campaign
Zimbabwe accounted for 17% of TruScreen’s global sales in FY2024 and TruScreen
continues to work with the Ministry of Health and the National Aids Council to expand on
our screening in Masvingo province, where 14,000 women have been screened to date.
Re–validation of TruScreen for government programs is to be conducted in Mar-April 2025
and new tenders will be submitted for continuation of this program, with the Zimbabwe
Ministry of health wishing to extend the program to the capital, Harare.
17 million women of
screening age
Mexico
TruScreen has received COFEPRIS approval to be used in the public health system
in Mexico. Strategies for Growth
1. Public Sector TruScreen’s distributor is focusing on IMSS, the countries largest
health insurance agency, as the key target market for its activities to capitalize on this
approval.
2. Private Sector engage high use clinics via a series of webinars and the installation of
Free on Loan devices linked to a guaranteed minimum consumable usage per device.
46 million women of
screening age

30
Saudi Arabia
Commercial rollout commenced in FY2024, with Private Health
Insurancereimbursement for TruScreenavailable from most Private Health Insurers.
Sales is supported by a recently released report from 500 patient trial.
The investigators concluded that “the trial provides an evidence-based approach for
policymakers when selecting the optimal cervical cancer screening strategy in
countries without an established national screening program”.
11 million women of
screening age
Other Markets
Botswana, Rwanda, Eswatini, Jordan, Poland, North Macedonia, Serbia.
Russia and Central Asia
61 million women
of screening age
In October 2024 TruScreen was included in the Russian Cervical Cancer Screening Guideline
(listed as an ‘opto-electric screening device’) and TruScreen’s Russian distributor is also
expanding activities to include Kazakhstan, Kyrgyzstan, Belarus and Armenia

31
Contact us for more Information
Martin Dillon
CEO
M - +61 449 115 065
E – martindillon@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com
Guy Robertson
Chief Financial Officer

M – +61 407 983 270
E – guyrobertson@truscreen.com
TruScreen
Suite 3.03 18 Orion Rd
Lane Cove West NSW 2066
Australia
www.truscreen.com

32
Disclaimers
This presentation has been prepared by TruScreen Group Limited (the “Company”) and is dated 25 August 2023. This presentation contains summary
information about the Company and its activities which is current as at the date of this presentation. The information in this presentation is of a general
nature and does not purport to be complete nor does it contain all the information which a prospective investor may require in evaluating a possible
investment in the Company. This presentation should be read in conjunction with the Company’s annual report, market releases and other periodic and
continuous disclosure announcements, which are available at www.nzx.com. This presentation does not constitute an offer, advertisement or invitation in
any place in which, or to any person to whom, it would not be lawful to make such an offer, advertisement or invitation.
Not financial product advice
This presentation is for information purposes only and is not financial or investment advice or a recommendation to acquire the Company’s securities, and
has been prepared without taking into account the objectives, financial situation or needs of prospective investors. Before making an investment decision,
prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs and
consult a financial adviser, solicitor, accountant or other professional adviser if necessary.
Past performance
Any past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an
indication of future performance. No representations or warranties are made as to the accuracy or completeness of such information.
Future performance
This presentation includes certain “forward-looking statements” about the Company and the environment in which the Company operates. Forward-
looking information is inherently uncertain and subject to contingencies, known and unknown risks and uncertainties and other factors, many of which
are outside of the Company’s control, and may involve significant elements of subjective judgement and assumptions as to future events which may or
may not be correct. A number of important factors could cause actual results or performance to differ materially from any forward-looking statements.
No assurance can be given that actual outcomes or performance will not materially differ from the forward-looking statements. The forward-looking
statements are based on information available to the Company as at the date of this presentation. Except as required by law or regulation (including the
Listing Rules), the Company undertakes no obligation to provide any additional or updated information whether as a result of new information, future
events or results or otherwise.

33
References
1.WHO, HPV and Cervical Cancer Fact sheet, 11 November 2020, https://www.who.int/news-
room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer
2.WHO Cervical Cancer Elimination Modelling Consortium (CCEMC), 2020
3.Human papillomavirus and cancer (who.int)
4.Wei, Y., Wang, W., Cheng, M., Hong, Z., Gu, L., Niu, J., Di, W., & Qiu, L. (2021). Clinical evaluation of
a real-time optoelectronic device in cervical cancer screening.European journal of obstetrics,
gynecology, and reproductive biology,266, 182–186.
https://doi.org/10.1016/j.ejogrb.2021.09.027.
5.Vet, J. N., Haindl, J. P., Velasquez, C., Parker, L. J., Burns, M. I., Morrell, S., & Campion, M. J.. (2022).
A Performance Evaluation of an Optoelectronic Cervical Screening Device in Comparison to
Cytology and HPV DNA Testing.European Journal of Gynaecological Oncology,43(2), 213.
https://doi.org/10.31083/j.ejgo4302027
6.Central Intelligence Agency, The World Fact Book, CHINA, People and Society, Female ages 25-64
Years, visited 28 August 2020, https://www.cia.gov/library/publications/the-world-
factbook/geos/ch.html
7.Central Intelligence Agency, The World Fact Book, VIETNAM, People and Society, Female ages 25-
64 Years, visited 28 August 2020, https://www.cia.gov/library/publications/the-world-
factbook/geos/vm.html